Therapy With Carboplatin and Anti-PD-1 Antibodies Before Surgery Demonstrates Sustainable Anti-Tumor Effects for Secondary Cancers in Mice With Triple-Negative Breast Cancer

Patients with triple-negative breast cancer (TNBC) suffer an unfavorable prognosis. Carboplatin (CBDCA) as a cytotoxic reagent has been widely administered to patients with cancer including TNBC. Programmed cell death protein 1 (PD-1) is an immune checkpoint, blockade of which unleashes T cell funct...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Meizhuo, Wang, Tie, Ji, Litong, Bai, Shuping, Tian, Lining, Song, Hongjiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066228/
https://www.ncbi.nlm.nih.gov/pubmed/32194569
http://dx.doi.org/10.3389/fimmu.2020.00366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066228/
https://www.ncbi.nlm.nih.gov/pubmed/32194569
http://dx.doi.org/10.3389/fimmu.2020.00366

Ejemplares similares